Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction

European Heart Journal

Volumn 23, Issue 21, 2002, Pages 1670-1677

  De Zwaan, C ^a   Kleine, A H ^a   Diris, J H C ^a   Glatz, J F C ^c   Wellens, H J J ^a   Strengers, P F W ^b   Tissing, M ^b   Hack, C E ^b   Van Dieijen Visser, M P ^a   Hermens, W T ^c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

C1 inhibitor; Complement inhibition; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; CETOR; COMPLEMENT COMPONENT C1S INHIBITOR; CREATINE KINASE; FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE; TROPONIN T;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT INHIBITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIBRINOLYTIC THERAPY; HEART MUSCLE INJURY; HEART MUSCLE REPERFUSION; HUMAN; MALE; OPEN STUDY; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMPLEMENT ACTIVATION; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT C4; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; POSTOPERATIVE CARE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0036869137     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(02)93191-X     Document Type: Article

References (33)

1. Yasuda M, Takeuchi K, Hiruma M et al. The complement system in ischemic heart disease. Circulation 1990; 81: 156-63.
2. Hack CE, Wolbink GJ, Schalkwijk C, Speijer H, Hermens WT, Van den Bosch H. A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells. Immunology Today 1997; 18: 111-5.
3. Lagrand WK, Niessen HWM, Wolbink GJ et al. C-reactive protein co-localizes with complement in human hearts during acute myocardial infarction. Circulation 1997; 95: 97-103.
4. Pinckard RN, O'Rourke RA, Crawford MH et al. Complement localization and mediation of ischemic injury in baboon myocardium. J Clin Invest 1980; 66: 1050-6.
5. Rossen RD, Michael LH, Hawkins HK et al. Cardiolipin- protein complexes and initiation of complement activation after coronary artery occlusion. Circ Res 1994; 75: 546-55.
6. Hugo F, Hamdoch T, Mathey D, Schäfer H, Bhakdi S. Quantitative measurement of of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium. Clin Exp Immunol 1990; 81: 132-6.
7. Mathey D, Schofer J, Schäfer HJ et al. Early accumulation of the terminal complement complex in the ischemic myocardium after reperfusion. Eur Heart J 1994; 15: 418-23.
8. Amsterdam EA, Stahl GL, Pan H-L, Rendig SV, Fletcher MP, Longhurst JC. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol 1995; 268: H448-57.
9. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Circulation 1998; 97: 2259-67.
10. Griselli M, Herbert J, Hutchinson WL et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190: 1733-9.
11. Murohara T, Guo J-P, Delyani JA, Lefer AM. Cardioprotective effects of selective inhibition of two complement activation pathways in myocardial ischemia and reperfusion injury. Meth Find Exp Clin Pharmacol 1995; 17: 499-507.
12. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myovardial ischemia and reperfusion. Circulation 1995; 91: 393-402.
13. Horstick G, Heimann A, Götze O et al. Intracoronary application of C1-esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation 1997; 95: 701-8.
14. Kleine A, Mullers-Bournans M, Kop-Klaassen B, Koenderman A, Hack E, Hermens W. Cardioprotective effects of C1-inhibitor after coronary occlusion in dogs: comparison of effects in reperfused and non-reperfused hearts. Eur Heart J 2000; 21: 78.
15. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996; 334: 1630-4.
16. Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE. C1-esterase inhibitor: An anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000; 52: 91-112.
17. Levi M, Roem D, Kamp AM, de Boer JP, Hack CE, ten Cate JW. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb Haemostas 1993; 69: 141-6.
18. De Smet BJGL, de Boer JP, Agterberg J, Rigter G, Bleeker WK, Hack CE. Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-Inhibitor in rats. Blood 1993; 81: 56-61.
19. Wolbink G-J, Bollen J, Baars JW et al. Application of a monoclonal antibody against a neoepitope on activate C4 in an ELISA for the quantification of complement activation via the classical pathway. J Immunol Methods 1993; 163: 67-76.
20. Van der Laarse A, Vermeer F, Hermens WT et al. Effects of early intracoronary streptokinase on infarct size estimated from cumulative enzyme release rate. A randomized trial on 533 patients with acute myocardial infarction. Am Heart J 1986; 112: 672-81.
21. Van Domburg RT, Cobbaert C, Müller-Bardorff M et al. Time-dependent diagnostic performance of a rapid troponin T version 2 bedside test in patients with acute coronary syndromes. Scand J Clin Lab Invest 2000; 60: 665-75.
22. Bauernschmitt R, Böhrer H, Hagl S. Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA. Intensive Care Med 1998; 24: 635-8.
23. Fronhoffs S, Luyken J, Steuer K, Hansis M, Vetter H, Walger P. The effect of C1-esterase inhibitor in definite and suspected streptococcal toxic shock syndrome. Report of seven patients. Intensive Care Med 2000; 26: 1566-70, doi: 10.1007/s001340000654.
24. Strüber M, Hagl C, Hirt SW, Cremer J, Harringer W, Haverich A. C1-esterase inhibitor in graft failure after lung transplantation. Intensive Care Med 1999; 25: 1315-8.
25. Horstick G, Berg O, Heimann A et al. Application of C1- esterase inhibitor during reperfusion of ischemic myocardium. Dose-related beneficial versus detrimental effects. Circulation 2001; 104: 3125-31.
26. Tassani P, Kunkel R, Richter JA et al. Effect of C1-esterase inhibitor on capillary leak and inflammatory response syndrome during arterial switch operations in neonates. J Cardiothorac Vasc Anesth 2001; 15: 469-73, doi: 10.1053/jcan.2001.24989.
27. Entman ML, Smith CW. Postreperfusion inflammation: a model for reaction to injury in cardiovascular disease. Cardiovasc Res 1994; 28: 1301-11.
28. Ivey CL, Williams FM, Collins PD, Jose PJ, Williams TJ. Neutrophil chemoattractants generated in two phases during reperfusion of ischemic myocardium in the rabbit. J Clin Invest 1995; 95: 2720-8.
29. Birdsall HH, Green DM, Trial JA et al. Complement C5a, TGF-1, and MCP-1, in sequence, induce migration of monocytes into ischemic canine myocardium within the first one to five hours after reperfusion. Circulation 1997; 95: 684-92.
30. Fitch JCK, Rollins S, Matis L et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 1999; 100: 2499-506.
31. Frangi D, Gardinali M, Conciato L, Cafaro C, Pozzoni L, Agostoni A. Abrupt complement activation and transient neutropenia in patients with acute myocardial infarction treated with streptokinase. Circulation 1994; 89: 76-80.
32. Wuillemin WA, Eldering E, Citarella F et al. Modulation of contact system proteases by glycosaminoglycans. J Biol Chem 1996; 271: 12913-8.
33. Citarella F, Wuillemin WA, Lubbers YT, Hack CE. Initiation of contact system activation in plasma is dependent on factor XII autoactivation and not on enhanced susceptibility of factor XII for kallikrein cleavage. Br J Haematol 1997; 99:197-205.